Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glucose Intolerance

Conditions

Glucose Intolerance

Trial Timeline

Aug 16, 2011 → Apr 9, 2012

NCT ID

NCT01405911

About Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg

Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg is a phase 2 stage product being developed by Merck for Glucose Intolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT01405911. Target conditions include Glucose Intolerance.

What happened to similar drugs?

4 of 6 similar drugs in Glucose Intolerance were approved

Approved (4) Terminated (3) Active (1)

✅Exenatide + MetforminEli LillyApproved

✅Candesartan + PlaceboAstraZenecaApproved

✅Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved

✅cyclosporine micro-emulsionNovartisApproved

🔄Ramipril + RosiglitazonePfizerPhase 3

❌UX007 + PlaceboUltragenyx PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01405911	Phase 2	Completed	Aug 16, 2011	Apr 9, 2012	Glucose Intolerance

Competing Products

17 competing products in Glucose Intolerance

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
Exenatide + Metformin	Eli Lilly	Approved	43
AZD1656	AstraZeneca	Phase 1	29
Candesartan + Placebo	AstraZeneca	Approved	35
Sitagliptin-Metformin + Metformin + Placebo pill	Merck	Approved	43
Comparator: exenatide + Comparator: exenatide + Comparator: Placebo	Merck	Phase 1	29
Placebo + Januvia	Merck	Phase 2	27
cyclosporine micro-emulsion	Novartis	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
Triheptanoin	Ultragenyx Pharmaceutical	Pre-clinical	20
UX007	Ultragenyx Pharmaceutical	Phase 2	21
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 3	26
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	25
Triheptanoin	Ultragenyx Pharmaceutical	Phase 2	29
UX007 + Placebo	Ultragenyx Pharmaceutical	Phase 2	29
GFT505 80mg + Placebo	Genfit	Phase 2	25